用于治疗恶性脑胶质瘤的被动免疫治疗策略。
Passive immunotherapeutic strategies for the treatment of malignant gliomas.
机构信息
Department of Neurosurgery, University of California Los Angeles, Los Angeles, CA 90095-1761, USA.
出版信息
Neurosurg Clin N Am. 2012 Jul;23(3):481-95. doi: 10.1016/j.nec.2012.04.008.
Abstract
This review provides historical and recent perspectives related to passive immunotherapy for high-grade gliomas. The authors discuss approaches that use lymphokine-activated killer cells, cytotoxic T lymphocytes, and monoclonal antibodies.
摘要
这篇综述提供了关于高级别神经胶质瘤被动免疫治疗的历史和最新观点。作者讨论了使用淋巴因子激活的杀伤细胞、细胞毒性 T 淋巴细胞和单克隆抗体的方法。
相似文献
1
Passive immunotherapeutic strategies for the treatment of malignant gliomas.用于治疗恶性脑胶质瘤的被动免疫治疗策略。
Neurosurg Clin N Am. 2012 Jul;23(3):481-95. doi: 10.1016/j.nec.2012.04.008.
2
Immunotherapy for glioma: promises and challenges.免疫疗法治疗脑胶质瘤：前景与挑战。
Neurosurg Clin N Am. 2012 Jul;23(3):357-70. doi: 10.1016/j.nec.2012.05.001.
3
Clinical trials with immunotherapy for high-grade glioma.免疫疗法治疗高级别胶质瘤的临床试验。
Neurosurg Clin N Am. 2012 Jul;23(3):459-70. doi: 10.1016/j.nec.2012.04.003. Epub 2012 Jun 8.
4
Overview of cellular immunotherapy for patients with glioblastoma.胶质母细胞瘤患者的细胞免疫疗法概述。
Clin Dev Immunol. 2010;2010. doi: 10.1155/2010/689171. Epub 2010 Oct 4.
5
[Immunotherapy for malignant glioblastoma].[恶性胶质母细胞瘤的免疫疗法]
No Shinkei Geka. 1995 Mar;23(3):195-206.
6
Clinical immunotherapy for brain tumors.脑肿瘤的临床免疫治疗
Neuroimaging Clin N Am. 2002 Nov;12(4):641-64. doi: 10.1016/s1052-5149(02)00027-8.
7
Mechanisms of immunomodulation in human glioblastoma.人胶质母细胞瘤的免疫调节机制。
Immunotherapy. 2011 Apr;3(4 Suppl):42-4. doi: 10.2217/imt.11.39.
8
Armed hunter killers: discerning the role of adoptive T-cell transfer for glioblastoma.武装杀伤性T细胞：洞悉过继性T细胞转移在胶质母细胞瘤中的作用
Immunotherapy. 2015;7(5):481-5. doi: 10.2217/imt.15.22.
9
Tumor-Specific T Cell Activation in Malignant Brain Tumors.恶性脑肿瘤中的肿瘤特异性 T 细胞激活。
Front Immunol. 2020 Feb 13;11:205. doi: 10.3389/fimmu.2020.00205. eCollection 2020.
10
HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.HER2 特异性 T 细胞靶向原发性脑胶质瘤干细胞并诱导自体实验性肿瘤消退。
Clin Cancer Res. 2010 Jan 15;16(2):474-85. doi: 10.1158/1078-0432.CCR-09-1322. Epub 2010 Jan 12.
引用本文的文献
1
The Evolving Landscape of Antibody-Drug Conjugates: In Depth Analysis of Recent Research Progress.抗体药物偶联物的发展现状：对近期研究进展的深入分析。
Bioconjug Chem. 2023 Nov 15;34(11):1951-2000. doi: 10.1021/acs.bioconjchem.3c00374. Epub 2023 Oct 11.
2
T Cell Epitope Prediction and Its Application to Immunotherapy.T 细胞表位预测及其在免疫治疗中的应用。
Front Immunol. 2021 Sep 15;12:712488. doi: 10.3389/fimmu.2021.712488. eCollection 2021.
3
NKp30 - A prospective target for new cancer immunotherapy strategies.NKp30 - 一种新的癌症免疫治疗策略的前瞻性靶标。
Br J Pharmacol. 2020 Oct;177(20):4563-4580. doi: 10.1111/bph.15222. Epub 2020 Aug 26.
4
Receptor-Targeted Glial Brain Tumor Therapies.受体靶向胶质脑瘤治疗方法。
Int J Mol Sci. 2018 Oct 25;19(11):3326. doi: 10.3390/ijms19113326.
5
Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV.性传播病毒感染的免疫治疗策略：HIV、HSV和HPV。
Cell Immunol. 2016 Dec;310:1-13. doi: 10.1016/j.cellimm.2016.08.001. Epub 2016 Aug 3.
本文引用的文献
1
Bevacizumab at recurrence in high-grade glioma.贝伐单抗治疗高级别胶质瘤复发。
Neurol Sci. 2011 Nov;32 Suppl 2:S251-3. doi: 10.1007/s10072-011-0799-6.
2
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.卡铂、伊立替康和贝伐珠单抗治疗贝伐珠单抗初治复发性胶质母细胞瘤的 II 期研究。
J Neurooncol. 2012 Mar;107(1):155-64. doi: 10.1007/s11060-011-0722-2. Epub 2011 Oct 11.
3
Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.通过针对野生型和变异 III 型突变表皮生长因子受体的单克隆抗体 D2C7 对恶性神经胶质瘤进行放射性免疫靶向治疗。
Nucl Med Biol. 2012 Jan;39(1):23-34. doi: 10.1016/j.nucmedbio.2011.06.005. Epub 2011 Sep 29.
4
Using bevacizumab in the fight against malignant glioma: first results in Asian patients.贝伐珠单抗在恶性脑胶质瘤治疗中的应用：亚洲患者的初步结果。
Hong Kong Med J. 2011 Aug;17(4):274-9.
5
Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe?复发性胶质母细胞瘤的临床终点：抗血管生成药物是友是敌？
Expert Rev Anticancer Ther. 2011 May;11(5):657-60. doi: 10.1586/era.11.44.
6
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.贝伐珠单抗联合标准放疗和替莫唑胺序贯贝伐珠单抗、替莫唑胺和伊立替康治疗新诊断的胶质母细胞瘤。
Clin Cancer Res. 2011 Jun 15;17(12):4119-24. doi: 10.1158/1078-0432.CCR-11-0120. Epub 2011 Apr 29.
7
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.贝伐珠单抗治疗临床试验之外的复发性高级别胶质瘤患者的临床结局。
Acta Oncol. 2011 Jun;50(5):630-5. doi: 10.3109/0284186X.2011.572913. Epub 2011 Apr 18.
8
Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis.贝伐单抗治疗复发性多形性胶质母细胞瘤：一项荟萃分析。
J Natl Compr Canc Netw. 2011 Apr;9(4):403-7. doi: 10.6004/jnccn.2011.0037.
9
Ex vivo gene transfer for improved adoptive immunotherapy of cancer.体外基因转移提高癌症过继免疫治疗。
Hum Mol Genet. 2011 Apr 15;20(R1):R93-9. doi: 10.1093/hmg/ddr102. Epub 2011 Mar 17.
10
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.贝伐珠单抗治疗恶性脑胶质瘤的矛盾效应。
Neurology. 2011 Jan 4;76(1):87-93. doi: 10.1212/WNL.0b013e318204a3af.
Zotero 插件